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Abstract
Background: Altered maternal inflammatory responses play a role in the development of preeclampsia and the hemolysis,
elevated liver enzymes and low platelets (HELLP) syndrome. We examined whether allelic variants of the innate immune
receptors Toll-like receptor 4 (TLR4) and nucleotide-binding oligomerization domain 2 (NOD2), that impair the inflammatory
response to endotoxin, are related to preeclampsia and HELLP syndrome.
Methods and Findings: We determined five common mutations in TLR4 (D299G and T399I) and NOD2 (R702W, G908R and
L1007fs) in 340 primiparous women with a history of early-onset preeclampsia, of whom 177 women developed HELLP
syndrome and in 113 women with a history of only uneventful pregnancies as controls. In addition, we assessed plasma
levels of pro-inflammatory biomarkers C-reactive protein, interleukin-6, soluble intercellular adhesion molecule-1, fibrinogen
and von Willebrand factor in a subset of 214 women included at least six months after delivery. After adjustment for
maternal age and chronic hypertension, attenuating allelic variants of TLR4 were more common in women with a history of
early-onset preeclampsia than in controls (OR 2.9 [95% CI 1.2–6.7]). Highest frequencies for TLR4 variants were observed in
women who developed HELLP syndrome (adjusted OR 4.1 [95% CI 1.7–9.8]). In addition, high levels of interleukin-6 and
fibrinogen were associated with a history of early-onset preeclampsia. Combined positivity for any of the TLR4 and NOD2
allelic variants and high levels of interleukin-6 was 6.9-fold more common in women with a history of early-onset
preeclampsia (95% CI 2.1–23.2) compared to controls.
Conclusions: We observed an association of common TLR4 and NOD2 gene variants, and pro-inflammatory phenotype with
a history of early-onset preeclampsia and HELLP syndrome. These findings suggest involvement of the maternal innate
immune system in severe hypertensive disorders of pregnancy.
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Introduction
Preeclampsia is a complex multi-system disease of unknown
origin, characterized by hypertension and proteinuria in the
second half of pregnancy, with potentially life-threatening
consequences for both mother and baby [1]. Worldwide an
estimated 4.2 million women are affected by preeclampsia each
year and an annual 60,000 maternal deaths are attributed to the
disorder [2].
The inflammatory system has a pivotal role in the pathogenesis
of common placental and hypertensive disorders of pregnancy,
including preeclampsia, intra-uterine growth restriction (IUGR)
and the hemolysis, elevated liver enzymes and low platelets
(HELLP) syndrome [1,3,4]. Maternal adaptation to pregnancy
requires a prominent and tightly regulated interplay of innate and
adaptive immunity to allow normal growth and development of
the semi-allogeneic fetus. Inappropriate inflammatory patterns
have been related to abnormal trophoblast invasion [5],
endothelial damage [3], and renal dysfunction [6]. Furthermore,
preeclampsia is characterized by excessive production of pro-
inflammatory cytokines and chemokines [7], as well as distur-
bances in immunosuppressive regulators such as IL-10 and TGF-b
[7,8]. Endotoxin or lipopolysaccharide (LPS) is a potent antigen
normally present in gram-negative bacteria, known to induce a
systemic pro-inflammatory reaction. LPS-mediated inflammation
is believed to be of critical importance in many systemic infectious
and non-infectious or auto-immune disorders, including sepsis [9],
allergic asthma [10] and inflammatory bowel diseases [11]. In an
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animal model, Faas and colleagues demonstrated that infusion of
low-dose LPS induces a preeclampsia-like syndrome, including
hypertension, proteinuria and glomerular endotheliosis [12]. LPS
leads to release of pro-inflammatory cytokines through activation
of two major pattern recognition receptors (PRRs) present on
innate immune cells (macrophages, NK cells and dendritic cells),
i.e. the extracellular Toll-like receptor 4 (TLR4), and the
intracellular nucleotide oligomerization domain 2 (NOD2) pro-
tein, also known as the caspase-activating recruitment domain 15
(CARD15). Upon activation, these receptors signal cells of the
adaptive immune system (mainly T cells) via production of nuclear
factor kappa B and release of pro-inflammatory cytokines (IL-1b,
IL-6, TNF-a) to constitute an inflammatory response necessary for
effective clearance of the harmful pathogen. Allelic variants of
TLR4 and NOD2 have been associated with an attenuated
immune response to LPS, leading to inappropriate inflammatory
patterns which can be both ineffective in dealing with an infectious
agent, as well as cause the adverse effects of uncontrolled
inflammation [13,14]. Genetic variation in the extracellular
(TLR4) and intracellular (NOD2) endotoxin sensing system have
been related to sepsis [9], Crohn’s disease [11,15], premature
delivery [16] and atherogenesis [17]. In this study we examined
the contribution of two common allelic variants of the TLR4
(D299G and T399I) and three common allelic variants of NOD2
(R702W, G908R and L1007fs) to the pathogenesis of early-onset
preeclampsia and HELLP syndrome. In addition, we determined
plasma levels of biomarkers representative for the acute-phase
inflammatory response (C-reactive protein, fibrinogen, interleukin-
6, soluble intercellular adhesion molecule-1 and von Willebrand
factor) in women with a history of early-onset preeclampsia and
controls with only uneventful pregnancies at least six months after
delivery. We hypothesized that allelic variants of TLR4 and
NOD2, as well as high circulating levels of pro-inflammatory
biomarkers after delivery would relate to a history of early-onset
preeclampsia and HELLP syndrome.
Methods
Participants
Participants were recruited between August 1995 and Septem-
ber 2005 in four tertiary referral centres (University Medical
Center Utrecht; N= 280, Leiden University Medical Center;
N= 45, St Radboud University Medical Center Nijmegen; N= 98
and Maxima Medical Center Veldhoven; N= 30) in the Nether-
lands. Inclusion criteria for cases were primiparity, a history of
preeclampsia or HELLP syndrome, and delivery before 34 weeks
of gestation. Controls were women with a history of at least one
uneventful pregnancy, recruited at the University Medical Center
Utrecht (N= 75) and St Radboud University Medical Center
Nijmegen (N=38). At inclusion, demographic data and whole
blood samples for DNA isolation were obtained from all
participants. For a subgroup of 214 women (all recruited at the
University Medical Center Utrecht, at least six months after
delivery; N= 144 cases), plasma samples were available for
analysis of metabolic, lipid and inflammatory markers. Inclusion
criteria, sample collection and data acquisition were previously
described elsewhere [18–20]. The study was approved by the
Medical Ethics Committee of the University Medical Center
Utrecht, the Medical Ethics Committee of the University Medical
Center Nijmegen, the Institutional Review Board of the Maxima
Medical Center Veldhoven and the Medical Ethics Committee of
the Leiden University Medical Center, and written informed
consent was obtained from all participants. Preeclampsia was
defined according to the criteria of the International Society for
the Study of Hypertension in Pregnancy [21], as de novo
hypertension above 90 mm Hg at two or more consecutive
measurements, at least 4 hours apart, and proteinuria above 0.3 g
per 24 hours. HELLP syndrome was defined according to
previously described criteria [22], as hemolysis (defined as serum
lactate dehydrogenase (LDH) .600 U/L and/or haptoglobin
#0.3 g/L), elevated liver enzymes (serum aspartate aminotrans-
ferase (AST) .70 U/L and/or serum alanine aminotransferase
(ALT) .70 U/L), and a low platelet count (,1006109/L). Small-
for-gestational age (SGA) was defined as birth weight below the
5th centile, based on the Dutch population charts [23]. Finally,
chronic hypertension was defined as hypertension, treated with
anti-hypertensive medication initiated before first pregnancy.
Procedures
Genomic DNA was isolated from blood, using standard
commercially available kits (Gentra Systems, Minneapolis, MN,
USA). Two common missense mutations of the TLR4 gene
(GenBank: NM_138554; OMIM: 603030) were detected by a
previously described polymerase chain reaction (PCR) [24], based
on exonuclease degradation of dual labelled allele-specific
oligonucleotides: a substitution of adenosine by guanine at position
896 in the fourth exon, leading to replacement of aspartic acid by
glycine at amino acid position 299 in the extracellular domain of
TLR4 (D299G; RefSNP ID: rs4986790) and a frequently co-
segregating mutation, leading to an amino acid substitution at
position 399 of threonine by isoleucine (T399I; RefSNP ID:
rs4986791). In addition, three common allelic variants of the
NOD2 gene (GenBank: NM_022162; OMIM: 605956) were
determined by a similar genotyping method: a substitution of
cytosine by thymine at position 2104 leading to amino acid
replacement of arginine by tryptophan at position 702 in the
fourth exon (R702W; RefSNP ID: rs2066844), a substitution of
cytosine by guanine at position 2722 leading to replacement of
glycine at arginine at position 908 in the eighth exon (G908R;
RefSNP ID: rs2066845) and an insertion of cytosine at position
3020 leading to an amino acid frame shift from leucine at position
1007 (L1007fs; RefSNP ID: rs2066847). Primers and probes were
designed by prevalidated commercially available custom-made
development kits (Assay-by-Design; Applied Biosystems, Foster
City, CA, USA) and performed on a 384-wells PCR machine
(Biometra, Goettingen, Germany) and an automated fluorimeter
(Fluostar Galaxy, BMG LABTECH, Offenburg, Germany), as
described in detail before [24]. Genotyping assays were performed
by operators blinded to phenotypic outcome, replicated in a
randomly selected sample set and included control samples for
each of the genotypes, verified by DNA sequencing.
For phenotype analysis, fasting blood samples were collected,
immediately centrifuged and plasma was stored at 280uC until
further analysis. Plasma concentrations of high sensitivity C-
reactive protein (CRP) were determined using a commercially
available reagents for nephelometric analysis (Dade Behring,
Marburg, Germany). Fibrinogen levels were measured by the
Claus’ clotting method using the Sta-R automatic coagulation
analyzer with STA Fibrinogen reagent (Diagnostic Stago,
Taverny, France). Plasma levels of interleukin-6 (IL-6) and soluble
intercellular adhesion molecule-1 (sICAM-1) were assessed by
means of commercially available enzyme-linked immunosorbent
assay development kits (R&D Systems, Minneapolis, MN, USA),
according to the manufacturer’s protocol. Plasma antigen levels of
von Willebrand factor (vWf) were measured with an enzyme-
linked immunosorbent assay using commercial antibodies (Dako,
Glostrup, Denmark), as previously described [25]. Intra-assay and
inter-assay coefficients of variability were ,10% for all assays.
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Lower detection limit for C-reactive protein was 0.15 mg/L, with
a coefficient of variability of 3.3%. The fibrinogen assay had a
lower detection limit of 0.28 g/L, with a coefficient of variability of
4.1%. For the commercial ELISA kits to measure IL-6, the lower
detection limit in plasma was 1.0 pg/mL with a coefficient of
variability of 7.2%, and to measure sICAM, the lower limit was
31 ng/mL with a coefficient of variability of 7.1%. Finally, von
Willebrand factor assay had a lower detection limit of 1.2 mg/mL
with a coefficient of variability of 8.0%.
Statistics
Baseline and clinical outcome variables were compared by
Students t-tests for continuous variables and Chi-squared tests for
categorical variables where appropriate. The relative contributions
of TLR4 and NOD2 genotypes to the occurrence of early-onset
preeclampsia were estimated by logistic regression analysis, and
expressed as odds ratios with 95% confidence intervals (CIs).
Because time of diagnosis and the presence of pre-existent
hypertensive disorders could theoretically influence the diagnosis
of preeclampsia, odds ratios were adjusted for age at first delivery
and chronic hypertension, by multivariable logistic regression
analysis. To account for their skewed distributions, circulating
levels of inflammatory biomarkers were presented as medians with
interquartile range, and comparisons between cases and controls
were based on Mann-Whitney U statistics. Correlations between
continuous variables were calculated with the use of age-adjusted
Spearman partial correlation coefficients. In addition, interactions
between inflammatory markers and allelic variants of TLR4 and
NOD2 were evaluated by calculating odds ratios for occurrence of
preeclampsia or HELLP syndrome, according to each tertile of the
plasma level distribution of the control population, also by logistic
regression analysis. To evaluate the combined contributions of
genotype and tertiles of plasma inflammatory markers, trend
analysis was performed by logistic regression analysis among the
following groups using a regression equation for early-onset
preeclampsia [26]: women negative for any of the minor allelic
variants of TLR4 and NOD2 and within the lowest tertile of
plasma inflammatory markers, according to the distribution
among controls (reference group; score = 1), women negative for
allelic variants within the highest tertiles and women positive for
one or more allelic variants within the lower two tertiles (score = 2),
and women positive for one or more allelic variants within the
highest tertiles (score = 3). Subsequently, multivariable logistic
regression analysis was used to control for age at inclusion,
differences in body-mass index (less than 20, 20 to 25, 25 to 30 and
30 or more), interval between delivery and inclusion, current
smoker (yes or no), and chronic hypertension (yes or no).
Results
Women with a history of early-onset preeclampsia had
significantly higher body-mass index and slightly lower age at
enrolment in the study than controls. Among the 340 women with
first pregnancy early-onset preeclampsia, 177 women developed
HELLP syndrome, and 98 delivered small-for-gestational age
infants (Table 1).
All genotype frequencies were in Hardy-Weinberg equilibrium
with allele frequencies for TLR4 at 7.4% for the D-allele at
position 299 and 7.2% for the I-allele at position 399, and for
NOD2 at 4.4% for the W-allele at position 702, 1.0% for the R-
allele at position 908 and 1.8% for the frame shift deletion at
position 1007. As expected, TLR4 D299G and T399I genotypes
showed a high co-segregation rate of 97%.
Among all women with a history of early-onset preeclampsia,
positivity for one or more of the minor allelic variants of TLR4
was observed significantly more often than in controls, with an
Table 1. Baseline Characteristics, First Pregnancy Outcome and Plasma Markers of Inflammation and the Acute-Phase Response
Characteristic Early-Onset Preeclampsia (N=340) Controls (N=113) P Value
Maternal age at inclusion – yr 30.664.4 32.864.3 ,0.001
Maternal age at delivery – yr 29.764.4 31.164.2 0.005
Height – cm 16967 169610 0.73
Weight – kg 73615 66611 0.001
Body-mass index 25.765.3 22.764.0 ,0.001
Chronic hypertension – no. (%) 61 (19) 7 (7) ,0.001
Ethnicity – caucasian no. (%) 326 (97) 112 (99) 0.21
Current smoker – no. (%) 43 (17) 19 (21) 0.31
Smoking during pregnancy { – no. (%) 59 (18) 16 (18) 0.92
Gestational age at delivery { – wk 29.962.4 40.061.3 ,0.001
Infant’s birth weight { – g 10906427 35766469 ,0.001
Hellp-syndrome { – no. (%) 177 (51) - -
Small-for-gestational-age infant (,5th centile) { – no. (%) 98 (28) 1 (1) ,0.001
C-reactive protein – mg/L 0.962.8 0.661.0 0.05
Fibrinogen – g/L 2.861.2 2.561.4 0.02
Interleukin-6 – pg/mL 3.662.7 2.862.4 0.002
sICAM-1 – ng/mL 1216148 1386121 0.04
von Willebrand factor – mg/mL 8.465.0 8.263.6 0.52
Data are expressed as means6SD, or as number (%) and compared by the independent sample T-test. Plasma inflammatory markers were measured in a subset of 214
women at least six months after delivery and are expressed as medians6interquartile range and compared by the nonparametric Mann-Whitney U test.
{Data represent outcomes of first pregnancy.
doi:10.1371/journal.pone.0001865.t001
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odds ratio of 3.3 (95% CI 1.5 to 7.5). This association between
TLR4 genotype and outcome remained significant (adjusted OR
2.9 [95% CI 1.2 to 6.7]), after adjustment for maternal age and
chronic hypertension in our multivariable model (Figure 1a). In
women with early-onset preeclampsia complicated by HELLP
syndrome (N= 177), positivity for one or more allelic variants of
TLR4 was observed in 1 out of 4 women, with an crude odds ratio
of 4.7 (95% CI 2.0 to 10.9) and adjusted odds ratio of 4.1 (95% CI
1.7 to 9.8), when compared to controls with only uneventful
pregnancies (Figure 1b). In addition, TLR4 polymorphisms were
significantly more common in women who developed HELLP
syndrome, when compared to women with preeclampsia only
(excluding those with HELLP) with an OR of 2.3 (95% CI 1.3 to
4.3) after adjustment for maternal age and chronic hypertension
(Figure 1c). Individually, each of the NOD2 allelic variants
(R702W, G908R and L1007fs) did not contribute to the
development of early onset preeclampsia with or without HELLP
syndrome (Figure 1).
Median levels of CRP, fibrinogen, and IL-6 were significantly
higher in women with a history of early-onset preeclampsia
(Table 1). Conversely, median sICAM-1 levels were lower in cases
and vWf levels showed no difference between cases and controls.
We observed no difference in median plasma levels of inflamma-
tory markers between women with a history of HELLP syndrome,
compared to women with early-onset preeclampsia without
HELLP syndrome (data not shown).
Correlations between plasma levels of inflammatory markers
(CRP, IL-6, sICAM-1), acute-phase reactants (fibrinogen, vWf)
and baseline variables are shown in Table 2. In women with a
history of early-onset preeclampsia significant positive correlations
were observed between CRP, sICAM-1, fibrinogen and vWf,
ranging from 0.20 for CRP and vWf to 0.38 for fibrinogen and
vWf and for CRP and fibrinogen. In addition, body-mass index
related to plasma levels of fibrinogen in cases (0.30) and CRP in
controls (0.32). Interestingly, plasma levels of CRP, fibrinogen and
vWf were unaffected by the time between delivery and enrolment
for both cases and controls. However, IL-6 levels showed a
significant negative correlation with interval between delivery and
inclusion for controls only (20.33). This correlation was not
observed within women with a history of early-onset preeclampsia,
probably due to the significantly higher median IL-6 levels in
women with a history of early-onset preeclampsia (3.662.7 pg/
mL compared to 2.862.4 pg/mL; p= 0.002). A similar effect of
interval between delivery and inclusion upon sICAM-1 levels
(20.28; p,0.001) was observed for cases only.
Table 3 shows the relationship between plasma inflammatory
markers measured at least six months after delivery and history of
early-onset preeclampsia, according to tertiles based on the
distribution of plasma levels within the control group of women
with a history of at least one uneventful pregnancy. Higher
circulating IL-6 levels within both the mid and highest tertiles were
observed more frequently in women with a history of early-onset
preeclampsia compared to controls (P for trend ,0.001), with an
unadjusted OR of 3.4 for the mid tertile (95% CI 1.5 to 7.7) and
4.9 for the highest tertile (95% CI 2.2 to 11.0). Adjustment for
interval between delivery and enrolment, age at inclusion, body-
mass index, chronic hypertension and smoking did not affect this
relationship. In addition, a history of early-onset preeclampsia was
related to lower plasma levels of sICAM-1. After adjustment for
confounding variables, ORs (95% CI) for early-onset preeclampsia
were 0.3 (0.1 to 0.9; P for trend 0.02) for both the mid and highest
tertiles of sICAM-1.
Median levels of CRP, IL-6, sICAM-1, fibrinogen and sICAM-
1 showed no direct association with heterozygous, homozygous or
Figure 1. Association of Early-Onset Preeclampsia and HELLP
Syndrome with Common Allelic Variants of TLR4 and NOD2
Related to Impaired Innate Inflammatory Responses to Endo-
toxin. Odds ratios (95% confidence intervals) for carrying either
heterozygous or homozygous common functional allelic variants of
TLR4 (D299G and T399I) and NOD2 (R702W, G908R and L1007fs) are
presented as unadjusted values (closed symbols) and were adjusted for
maternal age at first delivery and chronic hypertension (open symbols).
Comparisons were made between women with a history of early-onset
preeclampsia and controls with a history of only uneventful pregnancies
(A), between women with a history of early-onset HELLP syndrome and
controls with a history of only uneventful pregnancies (B) and between
women with a history of early-onset HELLP syndrome and women with a
history of early-onset preeclampsia without HELLP syndrome (C).
doi:10.1371/journal.pone.0001865.g001
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combined positivity for any of the TLR4 and NOD2 allelic
variants (all P values .0.05 after group comparison by Kruskal-
Wallis testing; data not shown). Nonetheless, increasing tertiles of
interleukin-6 and fibrinogen levels were associated with higher
odds ratios for early-onset preeclampsia in women carrying one or
more TLR4 or NOD2 mutations, compared to women with the
wild-type TLR4 or NOD2 genotype (Table 4). Overall, highest
odds ratios for early-onset preeclampsia were observed for women
carrying any of the five allelic variants of TLR4 or NOD2, within
the highest tertiles for IL-6 and fibrinogen, with ORs of 6.9 (95%
Table 2. Age-Adjusted Spearman Partial Correlation Coefficients between Plasma Inflammatory Biomarkers, Body-Mass Index, and
Interval Between Delivery and Enrolment among 70 Controls with a History of Only Uneventful Pregnancies and 144 Cases with a
History of Early-Onset Preeclampsia *
Controls
CRP Fibrinogen IL-6 sICAM vWf BMI Interval
CRP –
Fibrinogen 0.17 –
IL-6 20.21 0.10 –
sICAM 0.06 0.01 0.02 –
vWf 20.04 20.03 20.06 20.05 –
BMI 0.22 0.32{ 20.06 20.14 0.04 –
Interval 0.00 20.22 20.331 20.09 20.08 20.07 –
Cases
CRP Fibrinogen IL-6 sICAM vWf BMI Interval
CRP –
Fibrinogen 0.38" –
IL-6 0.14 0.12 –
sICAM 0.221 0.13 20.03 –
vWf 0.20{ 0.38" 0.11 20.03 –
BMI 0.301 0.12 0.05 0.08 20.05 –
Interval 20.04 20.03 0.03 20.28{ 0.13 20.07 –
*CRP denotes C-reactive protein, IL-6 interleukin-6, sICAM soluble intercellular adhesion molecule-1, vWf von Willebrand factor, BMI body-mass index and Interval time
between delivery and enrolment.
{P value,0.05
1P value,0.01
{P value,0.001
"P value,0.0001
doi:10.1371/journal.pone.0001865.t002
Table 3. Odds Ratios (95 Percent Confidence Intervals) for Women with a History of Early-Onset Preeclampsia, Compared to
Controls with Only Uneventful Pregnancies, According to Plasma Levels of Acute-Phase Inflammatory Biomarkers At Least Six
Months After Delivery
Unadjusted OR (95% CI) Adjusted OR (95% CI) Model 1 { Adjusted OR (95% CI) Model 2 1
Low (R) Mid High
P for
trend * Low (R) Mid High
P for
trend * Low (R) Mid High
P for
trend *
CRP, mg/L
[0.4–1.0]
1 0.7 (0.4–1.5) 1.6 (0.8–3.2) 0.16 1 0.8 (0.4–1.6) 1.6 (0.8–3.2) 0.17 1 0.4 (0.1–1.2) 0.9 (0.3–2.3) 0.86
Fibrinogen,
g/L [2.1–2.7]
1 0.9 (0.4–2.0) 2.1 (1.0–4.5) 0.03 1 0.8 (0.4–1.8) 1.9 (0.9–4.1) 0.07 1 1.6 (0.5–5.2) 1.2 (0.4–3.4) 0.71
IL-6, pg/mL
[2.1–3.5]
1 3.4 (1.5–7.7) 4.9 (2.2–11) ,0.001 1 2.9 (1.3–6.7) 3.9 (1.7–9.1) 0.002 1 3.6 (1.1–11) 4.6 (1.4–14) 0.01
sICAM-1, ng/
mL [93–179]
1 0.4 (0.2–0.8) 0.6 (0.3–1.3) 0.09 1 0.3 (0.2–0.7) 0.5 (0.3–1.0) 0.06 1 0.3 (0.1–0.9) 0.3 (0.1–0.9) 0.02
vWf, mg/mL
[7.1–9.4]
1 0.5 (0.3–1.1) 1.0 (0.5–1.9) 0.82 1 0.5 (0.2–1.1) 1.0 (0.5–2.0) 0.91 1 0.4 (0.2–1.2) 0.8 (0.3–1.9) 0.41
*P values represent trends accross increasing tertiles of plasma levels, by logistic regression analysis.
{Model 1 includes tertiles of plasma levels and interval between delivery and enrolment.
1Model 2 includes tertiles of plasma levels, interval between delivery and enrolment, age at inclusion, body-mass index, current smoking and chronic hypertension.
doi:10.1371/journal.pone.0001865.t003
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CI 2.1 to 23.2; P for trend 0.03 after adjustment for confounding
variables) for IL-6 and 3.8 (95% CI 1.2 to 11.8; adjusted P for
trend 0.04) for fibrinogen, respectively.
Discussion
We observed two novel findings from our study. First, that
maternal predisposition to early-onset preeclampsia and HELLP
syndrome is associated with allelic variants of genes that impair the
innate immune response, as demonstrated by the association with
common TLR4 polymorphisms. Second, that high circulating
levels of biomarkers representative of the inflammatory response
are associated with a history of early-onset preeclampsia and
HELLP syndrome in apparently healthy non-pregnant women.
Our findings are consistent with a central role for the maternal
innate immune system in the development of severe hypertensive
disorders of pregnancy. Moreover, our findings provide the first
evidence for a potential role of endotoxin responsiveness in the
susceptibility to preeclampsia and HELLP in humans.
Endotoxin, also known as lipopolysaccharide (LPS), has been
shown to induce pregnancy-specific inflammatory and endothelial
cell disturbances in rats, including hypertension and proteinuria
and characteristic glomerular endotheliosis lesions, with striking
similarities to the clinical syndrome of preeclampsia [12]. Taken
together with human data showing elevated circulating biomarkers
of soluble and cellular components of the innate immune system
before, during and after pregnancies complicated by early-onset
preeclampsia [3,7,27], we hypothesized that genetically encoded
individual differences in the inflammatory response to LPS could
influence maternal predisposition to the disorder. In the present
study, we demonstrated that the allelic variants D299G and T399I
of the extracellular pattern-recognition receptor TLR4, that
impair the inflammatory response to LPS, are related to a history
of early-onset preeclampsia. Alternately, we found no association
for three attenuating polymorphisms (R702W, G908R and
L1007fs) of the innate immune receptor NOD2, which binds the
bacterial component muramyl dipeptide (MDP) and is involved in
intracellular LPS-signalling [14].
Toll-like receptors (TLR) are considered as the most important
class of pattern-recognition receptors (PRRs), involved in host
defense against a variety of microbes by induction and regulation
of innate immunity [28]. At present 10 members of the TLR
TLR4 or NOD2 negative (n =170) TLR4 or NOD2 positive (n=60)
Low (R) High Low (R) High P Value{ Pa Value"
CRP 1 1.6 (0.7–3.5) 1.7 (0.6–4.5) 2.6 (0.8–8.0) 0.07 0.23
Fibrinogen 1 2.2 (1.0–5.1) 1.6 (0.5–4.5) 3.8 (1.2–11.8) 0.02 0.04
IL-6 1 4.3 (1.7–10.5) 3.6 (1.2–10.7) 6.9 (2.1–23.2) ,0.001 0.03
sICAM 1 0.7 (0.3–1.5) 1.6 (0.6–4.2) 0.8 (0.3–2.5) 0.76 0.27
vWf 1 0.9 (0.4–1.9) 1.3 (0.5–3.2) 1.9 (0.6–6.5) 0.43 0.57
*Data represent odds ratios and 95% CIs for early-onset preeclampsia compared to controls with at least one uneventful pregnancy, with respect to the reference group
(R) of women negative for the all minor allelic variants of TLR4 and NOD2 and with low values for plasma inflammatory markers. High values are values within the
highest tertiles of the distribution of plasma levels of the control group. Low values are values within the lowest tertiles (reference group) and values within the lower
two tertiles (TLR4 and NOD2 positive group), respectively; CRP denotes C-reactive protein, IL-6 interleukin-6, sICAM soluble intercellular adhesion molecule-1 and vWf
von Willebrand factor.
{P values for trend between groups, compared to the reference group (R) of women negative for allelic variants of TLR4 and NOD2, and with low levels of plasma
inflammatory markers, by univariable logistic regression analysis.
"Pa values for trend between groups, compared to the reference group (R), after adjustment for age at inclusion, interval between delivery and enrolment, body-mass
index, smoking and chronic hypertension, by multivariable logistic regression analysis.
doi:10.1371/journal.pone.0001865.t004
NOD2 negative (n =200) NOD2 positive (n=30)
Low (R) High Low High P Value{ Pa Value"
CRP 1 1.5 (0.7–3.1) 0.9 (0.3–2.8) 2.7 (0.5–13.4) 0.19 0.39
Fibrinogen 1 1.9 (0.9–4.2) 0.8 (0.2–2.6) 3.9 (0.8–19.3) 0.06 0.14
IL-6 1 4.5 (1.9–10.7) 2.1 (0.6–7.3) 9.2 (1.8–48.2) ,0.001 0.01
sICAM 1 0.6 (0.3–1.3) 1.0 (0.3–3.6) 0.7 (0.2–2.5) 0.34 0.10
vWf 1 0.8 (0.4–1.7) 0.7 (0.2–2.1) 2.1 (0.4–10.2) 0.85 0.93
Table 4. Genotype-Phenotype Interactions for TLR4 and NOD2 Genotypes and Plasma Inflammatory Markers, among Women with
a History of Early-Onset Preeclampsia and Controls with Only Uneventful Pregnancies *
TLR4 negative (n=194) TLR4 positive (n =36)
Low (R) High Low High P Value{ Pa Value"
CRP 1 1.6 (0.8–3.4) 3.9 (0.8–19.0) 3.0 (0.8–11.6) 0.05 0.13
Fibrinogen 1 2.2 (1.0–4.8) 3.5 (0.7–18.0) 4.7 (1.2–18.0) 0.007 0.02
IL-6 1 4.4 (1.9–10.3) 9.0 (1.7–46.5) 7.5 (1.8–30.8) ,0.001 0.006
sICAM 1 0.6 (0.3–1.3) 2.4 (0.7–9.0) 1.3 (0.2–6.7) 0.86 0.34
vWf 1 0.9 (0.5–1.9) 2.7 (0.7–10.1) 2.0 (0.4–10.1) 0.43 0.43
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family have been discovered in humans, of which TLR4 was first
recognized as a key receptor for the LPS component of Gram-
negative bacteria [13]. In addition, TLR4 has been shown to
recognize chlamydial heat shock protein [28,29], respiratory
syncytial virus fusion (F) protein [30] and molecular patterns of
malarial parasites [31]. Two functional mutations in the
extracellular LRR domain of human TLR4 have been identified
at position A896C, leading to A/G amino acid transition at
position 299, and C1196T, leading to T/I transition at position
399 [13,28]. Although co-segregation of the D299G and T399I
genotype occurs approximately 98% of Western populations, both
polymorphic variants appeared have been shown to independently
affect responsiveness to inhaled LPS. Recent stoichiometric
analysis of the D299G and T399I polymorphic variants of
TLR4 confirmed that the presence of each of the D299G and
T399I variants results in distinct structural changes in the ligand-
binding site of the receptor [32], which account for increased
susceptibility to infectious disease such as Gram-negative sepsis [9]
and malaria [31,33].
As TLR4 mutations have been shown to determine suscepti-
bility to a number of exogenous infectious agents, should we
consider potential infectious agents responsible for causing
preeclampsia or HELLP syndrome? Recently, it has indeed been
demonstrated that women with preeclampsia are prone to
periodontal infections, mainly caused by gram-negative bacteria
[34]. Other associations with preeclampsia have been observed for
adeno-associated virus 2 (AAV-2) [35], parvovirus B19 [36] and
cytomegalovirus [37]. Of interest, preeclampsia appears more
commonly in women who are seropositive for Chlamydia Pneumoniae
[38], which is a TLR4 dependent intracellular pathogen related to
the development of atheromatous lesions. Also, in a recent study of
304 pregnant women infected with P. Falciparum from South
Ghana, the D299G allelic variant of TLR4 was associated with a
5-fold increased risk of severe maternal anemia, as a result of
ineffective clearance of the malaria parasites [39]. Although the
interaction of TLR4 with P. Falciparum is not fully understood,
Krishnegowda and colleagues showed in vitro that TLR4 can be
activated by malarial glycosylphosphatidylinositols (GPIs) to
induce a pro-inflammatory response. It is, however, not known
if the D299G variant has any effect on this interaction [31].
Furthermore, in women with HELLP syndrome, in vitro
experiments show striking differences in monocyte handling of
LPS and gram-negative bacteria, when compared to women with
preeclampsia only [40]. In our study, TLR4 mutations were 2.4
times more common in women with HELLP syndrome than those
with preeclampsia only, suggesting that the TLR4 pathway might
be involved in the development of HELLP episodes in women
with early-onset preeclampsia. The HELLP syndrome is generally
considered the clinical extreme of preeclampsia, although its acute
onset and frequent spontaneous (albeit temporary) resolution
within days, even in those women who do not deliver [41,42],
suggests a more rapid deterioration initiated by temporally
released, yet unknown triggers. Our data suggest that exogenous
(infectious) agents involved in the TLR4 pathway, might be
candidate factors triggering HELLP syndrome within the already
immuno-modulated pre-eclamptic patient. On the other hand, it
has been suggested that TLR4 can be activated by number of
endogenous ligands involved in vascular damage, including heat-
shock protein 60 and the extracellular domain A (EDA) of
fibronectin [43,44]. Although these data are inconclusive because
of potential LPS contamination during analytical procedures, they
suggest a role for TLR4 in the so-called ‘‘danger hypothesis’’ [45].
This hypothesis states that tissue damage (either by endogenous or
exogenous agents) involves the release of signalling molecules that
are capable of eliciting an immediate immune reaction. In
preeclampsia, elevated circulating levels of cellular and sub-
cellular placental debris, including shedding of syncytiotrophoblast
membrane fragments [1,3], cell-free fetal DNA [46] and soluble
fms-like tyrosine kinase 1 (sFlt-1) [47], have been shown to induce
endothelial damage and precede onset of the clinical syndrome.
Interestingly, recent data by Kim and colleagues showed increased
expression of TLR4 in interstitial trophoblasts in placental bed
biopsies obtained from women with preterm preeclampsia,
consistent with a role for TLR4 at the feto-maternal interface
[48]. However, further studies are needed to investigate the
possibility that TLR4 acts as a danger receptor involved in
clearance of excess shedding of placental factors.
NOD2 is a member of the Apaf1/Ced4 superfamily of
apoptosis regulators, mainly expressed in monocytes, that acts as
an intracellular pattern recognition proteins (PRRs), containing
LRR domains similar to TLR4 [14]. Although NOD proteins
have an indirect role in LPS signaling, NOD2 primarily recognizes
a muramyl dipeptide (MDP) motif of peptiglycans found in
virtually all classes of bacteria, similar to the NOD1 ligand
diaminopimelic acid (DAP)-containing muramyl tripeptide (M-
TriDAP), found in gram-negative bacteria. In addition to its role
as an intracellular PRR, genetic mapping studies have identified
NOD2 as a strong susceptibility gene for Crohn’s disease [14,15].
The allelic variants L1007fs, R702W and G908R, each represent
three independent haplotypes commonly observed in patients with
European ancestry. Individuals homozygous for any of these
mutations exhibit an odds ratio of 42.1 for developing Crohn’s
disease. Recent studies have clarified the genetic and molecular
basis for this association, as reviewed in reference [14]. All three
variants affect the LRR-domain and are considered loss-of-
function mutations, likely to impair the recognition of microbial
components, interfering with appropriate activation of NF-kB in
monocytes, as well as disregulating NOD1 function. Also,
NOD2-/- mice exhibit a TH-1 type pro-inflammatory phenotype
following stimulation with TLR agonists [49], that suggests a more
fundamental role for NOD2 in controlling the innate immune
response. Although the role of NOD proteins in pregnancy and
placentation has not yet been investigated, protein expression and
induction of pro-inflammatory cytokine release after NOD1 and
NOD2 activation, was recently observed in first trimester
trophoblast cells [50]. In our study, no association was observed
for common NOD2 polymorphisms alone and a history of early-
onset preeclampsia or HELLP syndrome. This is in contrast to one
previous study by Goddard et al [51]. In this study, a significant
association was observed with NOD2 polymorphisms in women
with preeclampsia, mostly late-onset disease, by a global
haplotype-based approach. However, our data do suggest a
combined association of NOD2 allelic variants and maternal pro-
inflammatory phenotype with pregnancy outcome, which will be
further discussed below.
In addition, we observed elevated levels of circulating
biomarkers for inflammation and the acute-phase response in
women with a history of early-onset preeclampsia, when measured
at least six months after delivery, including CRP, fibrinogen and
IL-6, as compared to women who experienced only uneventful
pregnancies. Similar to previous reports [27], our data demon-
strate that non-pregnant women with a history of early-onset
preeclampsia more frequently exhibit a pro-inflammatory pheno-
type. Biomarkers of the acute-phase inflammatory response,
including CRP, fibrinogen, IL-6 and vWf, have all been shown
to be predictive of long-term cardiovascular risk, although not
independently adding to classic risk factor algorithms [52]. This
study suggests that an innate maternal pro-inflammatory pheno-
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type might be a common underlying risk factor for early-onset
preeclampsia and cardiovascular disease [53]. Surprisingly, we
observed an inverse relationship between sICAM-1 levels and history
of early-onset preeclampsia, which is in contrast with previous
findings by Freeman and colleagues [27]. However, their study
reported on sICAM-1 levels determined 20 years after delivery,
whereas our data represent samples collected at a mean interval
between delivery and enrolment of 0.7 years (range 0.5 to 8.5 years).
In this study, elevated plasma inflammatory biomarker levels
were unaffected by TLR4 and NOD2 genotype, and correlated
with increasing odds ratios for early-onset preeclampsia even after
careful correction for confounding factors, including age, interval
between delivery and enrolment, body-mass index, smoking status
and chronic hypertension. When examining the combined
association of TLR4 or NOD2 mutations and circulating levels
of inflammatory markers, highest odds ratios were observed for
women carrying allelic variants of TLR4 or NOD2, who were in
the upper tertiles of CRP, fibrinogen and IL-6. Compared to
women with plasma levels within the lowest tertiles of the control
distribution and negative for any of the TLR4 and NOD2
polymorphisms, the highest tertiles of fibrinogen and IL-6 and the
presence of attenuating allelic variants of TLR4 or NOD2 showed
both independent and combined associations with a history of
early-onset preeclampsia.
Our case-control study has several strengths and limitations. To
our knowledge, this study describes genotype and phenotype data
of the largest series of women with a history of early-onset
preeclampsia and HELLP syndrome yet, recruited over an interval
of more than a decade. However, we designed our study to include
only primiparous women, who delivered before 34 weeks of
gestation. Therefore, our data may not be extrapolated to
multiparae and women with a history of late-onset or near term
preeclampsia, as the pathophysiology of the disorder leading to
onset after 34 weeks’ gestation might differ from that which causes
early-onset disease [21]. A major strength of our study is in the
assessment of genetic single-nucleotide polymorphisms, which
unlike acquired or environmental risk factors are fixed at birth and
therefore provide a measure of life-long exposure, not likely to be
subject to confounding due to the timing of investigation [54].
Despite this considerable advantage, in any genetic association
study with a case-control design, selection bias and population
stratification should be considered. Conversely, because plasma
samples for analysis of inflammatory biomarkers were collected
after pregnancy, we cannot exclude the possibility that pregnancy
itself might have led to temporary or permanent changes in
inflammatory status. For some (IL-6 and sICAM-1) but not all
(CRP, fibrinogen and vWf) of the measured inflammatory markers
we indeed observed a significant correlation with the interval
between delivery and enrolment, suggestive of at least short-term
changes up to several months after pregnancy. Nonetheless, the
observed associations between high levels of interleukin-6 and
fibrinogen and a positive history of early-onset preeclampsia were
only moderately influenced by adjustment for interval between
delivery and sampling. At present no prospective data comparing
pre- and post-pregnancy levels of inflammatory markers are
available to provide a more conclusive answer to this question.
In summary, we are the first to show a relationship between
allelic variants of TLR4, that impair the innate inflammatory
response to LPS, early-onset preeclampsia and HELLP syndrome.
Next, we observed that a history of early-onset preeclampsia is
related to higher plasma levels of CRP, fibrinogen and IL-6 at least
six months after delivery. Our results support the hypothesis that
the innate immune system contributes to maternal susceptibility to
early-onset preeclampsia and HELLP syndrome. Therefore,
identification of components of the maternal innate inflammatory
system that predispose to hypertensive disorders of pregnancy
merits further investigation.
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